Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 19/20 | 0.62 |
| ▸ | DRD3 | P35462 | 3/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.62 |
| ▸ | DRD2 | P14416 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838469 | 0.82 | ADRB2 (0.65) | ADRB2ADRB1DRD3ADRA1DDRD2 | |
| Carmoterol SCHEMBL617717 | 0.82 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL13619222 | 0.82 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL10494565 | 0.82 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL11912044 | 0.82 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL5990417 | 0.82 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL10494358 | 0.82 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL465645 | 0.82 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL364838 | 0.81 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL10494473 | 0.81 | ADRB2 (0.98) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1529038-B1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | claimed |
| US-20150065490-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| EP-1529038-B1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| EP-1529038-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | Novartis AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016601-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885DRD3 711/4885 |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885DRD3 711/4885 |
| US-20150065490-A1 | ORGANIC COMPOUNDS | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885ADRB1 3/4885DRD3 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.